Key Highlights

  • A published market data snapshot from November 5, 2026 showed Progyny (NASDAQ:PGNY) at USD 34.20, up 13.62% in the latest session, 22.01% over one week and 32.25% over one month, a top Mid cap move.
  • Over three months the shares gained 33.80% and over six months 46.22%, with the price a week earlier near USD 28.03 and a month earlier near USD 25.86, both by simple arithmetic on the snapshot.
  • Revenue climbed 8.9% to USD 341.3 million in the third quarter, Net Income was USD 26.3 million, and adjusted EPS of USD 0.52 landed well ahead of the USD 0.31 published consensus.
  • For 2026 the company now projects Revenue between USD 1.365 billion and USD 1.385 billion, with adjusted EBITDA of USD 235.0 million to USD 240.0 million.

Profit Beat and Revenue Growth in the Third Quarter

Progyny (NASDAQ:PGNY) reported third quarter 2026 results on November 4, 2026, and the shares added 13.62% in the latest session of the snapshot. Revenue of USD 341.3 million was set against a published consensus of USD 340.76 million, while adjusted EPS of USD 0.52 beat USD 0.31, a gap of USD 0.21 according to published coverage. GAAP EPS was USD 0.32. Net income came to USD 26.3 million and adjusted EBITDA to USD 58.4 million. Eligible members averaged about 7.176 million, up 6.2%. The company ended with USD 196 million in cash, cash equivalents and marketable securities, no debt, and an undrawn USD 200 million revolving Credit facility. Revenue growth of 8.9% outpaced 6.2% member growth, which implies higher revenue per member.

How Buybacks Amplify a Profit Beat

The main driver is profit rather than revenue. Revenue cleared the published consensus by about USD 0.54 million (simple arithmetic), while adjusted EPS came in 68% above the USD 0.31 figure (calculated). Buybacks add support: the company bought back nearly 3 million shares for about USD 82.7 million during the quarter under its May 2026 program, roughly 5.5 million shares in total with about USD 51 million remaining. Including the November 2025 program, 14.3 million shares have been repurchased. Fewer shares lift EPS for a given profit. The 46.22% six month gain shows the rebound predates the report, so a low-base recovery and sector rotation into healthcare services may also have contributed, as general context.

Valuation Multiples, Renewal Cycles and Trading Risk

Trailing Earnings multiples sit near 32.72, while the forward multiple is 21.20 and the PEG Ratio 2.01, and analysts expect EPS of USD 1.25 this year and USD 1.42 next year. Trailing EPS was USD 0.92 against annual revenue of USD 1.29 billion. Revenue growth of 8.9% looks modest after a 32.25% monthly gain, and the valuation already assumes steady execution. Employer benefit contracts renew each year, and member utilization can move costs. Progyny (NASDAQ:PGNY) sits in the USD 2 billion to USD 10 billion mid cap band, a few trades can move the price, spreads can be wide and the move may reverse. The 52-week range and average Volume could not be confirmed.

Where Things Stand

Not assured. Progyny (NASDAQ:PGNY) surged 32.25% in a month largely because third quarter adjusted EPS of USD 0.52 beat USD 0.31 and buybacks remained active, after a 33.80% three month rally. In a published market data snapshot dated November 5, 2026 it ranks among the top mid caps over one week at 22.01%, and over one month. At USD 34.20 the shares are 46.22% higher over six months. Past gains do not predict future moves.